Quick Tips

APs: Need some clinical advice? Got 2 minutes? Watch our clinical oncology experts talk about the latest topics that will get you up to speed on current advances in the field. Here you'll find a range of topics where you can increase your knowledge quickly and then, when you have more than 2 minutes, you can participate in a deeper dive on each topic by accessing the full accredited version at JADPRO CE. Come back often as we are continually updating our 2 minute tips!


Search by:

Why is it important for APs to incorporate palliative care into the management of their patients, and what are some of the barriers to doing so?

Charles von Gunten, MD, PhD

Watch Video

Charles von Gunten, MD, PhD, on integrating palliative care into practice.

What are the risk factors and prevention strategies for throat cancer?



Watch Video

Julie E. Bauman, MD, MPH, on head and neck cancer: multimodality treatments.

What are the best ways to manage the adverse events of EGFR and ALK inhibitors?

Marianne Davies, DNP, ACNP, AOCNP, and Beth Eaby-Sandy, MSN, CRNP


Watch Video

Marianne Davies, DNP, ACNP, AOCNP, and Beth Eaby-Sandy, MSN, CRNP, on managing side effects for patients with thoracic tumors receiving multimodality therapy.

What are the best ways to minimize the adverse events of checkpoint inhibitors?

Beth Eaby-Sandy, MSN, CRNP
Marianne Davies, DNP, ACNP, AOCNP


Watch Video

Beth Eaby-Sandy, MSN, CRNP, and Marianne Davies, DNP, ACNP, AOCNP, on managing side effects for patients with thoracic tumors receiving multimodality therapy.

What are the best ways to manage the toxicities of current and emerging treatments for advanced prostate cancer?

Morgane Diven, PharmD, BCOP

Watch Video

Morgane Diven, PharmD, BCOP, on therapeutic advances in prostate cancer.

What do the data say about emerging agents for the treatment of nonmetastatic castration-resistant prostate cancer in men who have rapidly rising PSA levels?

Robert Dreicer, MD

Watch Video

Robert Dreicer, MD, on therapeutic advances in prostate cancer.

How do I distinguish the differential diagnoses of plasma cell dyscrasias?

Beth Faiman, PhD, APRN-BC, AOCN
Rachid Baz, MD

Watch Video

Beth Faiman, PhD, APRN-BC, AOCN, and Rachid Baz, MD, on advances in the management of plasma cell dyscrasias.

What are the appropriate management strategies for patients with MGUS and smoldering multiple myeloma?

Beth Faiman, PhD, APRN-BC, AOCN
Rachid Baz, MD

Watch Video

Beth Faiman, PhD, APRN-BC, AOCN, and Rachid Baz, MD, on advances in the management of plasma cell dyscrasias.

What is the best way to manage symptoms during treatment intended to cure head and neck cancer?

Abby Fuoto, RN, ANP

Watch Video

Abby Fuoto, RN, ANP, on head and neck cancer: multimodality treatments.

What are the best ways to monitor minimal residual disease in myeloid malignancies?

Melinda Tran, PharmD, BCOP
Kelda Gardner, PA-C, MHS

Watch Video

Melinda Tran, PharmD, BCOP, and Kelda Gardner, PA-C, MHS, on new directions in myeloid malignancies.

How can minimal residual disease be used to predict response to treatment for myeloid malignancies?

Melinda Tran, PharmD, BCOP
Kelda Gardner, PA-C, MHS

Watch Video

Melinda Tran, PharmD, BCOP, and Kelda Gardner, PA-C, MHS, on new directions in myeloid malignancies.

What are the rationales for lumpectomy, mastectomy, and mastectomy with reconstruction?

Sherry Goldman, NP, CBCN

Watch Video

Sherry Goldman, NP, CBCN, on breast cancer: the surgical implications.

What are the benefits and disadvantages of nipple-sparing surgery?

Sherry Goldman, NP, CBCN

Watch Video

Sherry Goldman, NP, CBCN, on breast cancer: the surgical implications.

What are the best ways to prevent and reduce adverse events of immune checkpoint inhibitors in patients with classical Hodgkin lymphoma?



Watch Video

Amy Goodrich, CRNP, on managing treatment-related events in classical Hodgkin lymphoma.

What is the best way to counsel patients with classical Hodgkin lymphoma on the early detection and prevention of adverse events?

Amy Goodrich, CRNP

Watch Video

Amy Goodrich, CRNP, on managing treatment-related events in classical Hodgkin lymphoma.

What are the indications of agents approved in 2017–2018 for patients with solid tumors?

Patrick J. Kiel, PharmD, BCPS, BCOP

Watch Video

Patrick J. Kiel, PharmD, BCPS, BCOP, on new drug updates in solid tumors.

What are the signs and symptoms of serious adverse events from the newly approved oncology drugs for solid tumors?

Patrick J. Kiel, PharmD, BCPS, BCOP

Watch Video

Patrick J. Kiel, PharmD, BCPS, BCOP, on new drug updates in solid tumors.

What are the best ways to manage the side effects of targeted treatments and immunotherapies for advanced and metastatic melanoma?

Lisa Kottschade, NP
Svetomir N. Markovic, MD, PhD

Watch Video

Lisa Kottschade, NP, and Svetomir N. Markovic, MD, PhD, on evolving therapies in managing melanoma.

How do I evaluate the data on immunotherapies used to treat advanced or metastatic melanoma?

Lisa Kottschade, NP
Svetomir N. Markovic, MD, PhD

Watch Video

Lisa Kottschade, NP, and Svetomir N. Markovic, MD, PhD, on evolving therapies in managing melanoma. 

What are the latest tests for molecular abnormalities in hematologic cancers?

Sandra E. Kurtin, PhDc, ANP-C, AOCN
Jennifer Knight, MD

Watch Video

Sandra E. Kurtin, PhDc, ANP-C, AOCN, and Jennifer Knight, MD, on differential diagnosis and testing in hematologic malignancies.

What do I need to know about preventing and reducing the side effects of agents used in patients with classical Hodgkin lymphoma?

Jose D. Sandoval-Sus, MD

Watch Video

Jose D. Sandoval-Sus, MD, on managing treatment-related events in classical Hodgkin lymphoma. 

What are the recent findings comparing the safety and efficacy of standard blood-thinning treatment with the newer direct oral anticoagulants?

Rowena Schwartz, PharmD, BCOP,

Watch Video

Rowena Schwartz, PharmD, BCOP, on the role of direct oral anticoagulants in venous thrombosis.

How do I evaluate the risks and benefits of treatment with direct oral anticoagulants?

Rowena Schwartz, PharmD, BCOP

Watch Video

Rowena Schwartz, PharmD, BCOP, on venous thrombosis: treatment risks and benefits.

What are the emerging data supporting combination therapies in chronic lymphocytic leukemia?

Lisa Nodzon, PhD, ARNP, AOCNP
Philip A. Thompson, MB

Watch Video

Lisa Nodzon, PhD, ARNP, AOCNP, and Philip A. Thompson, MB, on emerging data in indolent lymphomas.

How do I monitor patients with chronic lymphocytic leukemia/small lymphocytic lymphoma for 17p deletion at diagnosis and throughout the course of the disease?

Philip A. Thompson, MB
Lisa Nodzon, PhD, ARNP, AOCNP

Watch Video

Philip A. Thompson, MB, and Lisa Nodzon, PhD, ARNP, AOCNP, on sequencing therapies in indolent lymphomas.

What is the appropriate use of new agents for mantle cell lymphoma?

Barbara Rogers, CRNP, MN, AOCN, ANP-BC

Watch Video


Learn More On This Topic: Risk-Adapted Treatment of Aggressive B-Cell Lymphomas: Application of Novel Agents

Barbara Rogers, CRNP, MN, AOCN, ANP-BC, on treating mantle cell lymphoma.

What is the potential of emerging therapies?

Barbara Rogers, CRNP, MN, AOCN, ANP-BC

Watch Video


Learn More On This Topic: Risk-Adapted Treatment of Aggressive B-Cell Lymphomas: Application of Novel Agents

Barbara Rogers, CRNP, MN, AOCN, ANP-BC, on treating aggressive B-cell lymphomas.

What are the current treatments for relapsed/refractory DLBCL?

Barbara Rogers, CRNP, MN, AOCN, ANP-BC

Watch Video


Learn More On This Topic: Risk-Adapted Treatment of Aggressive B-Cell Lymphomas: Application of Novel Agents

Barbara Rogers, CRNP, MN, AOCN, ANP-BC, on treating aggressive B-cell lymphomas.

How do I manage minimal residual disease?

Jean A. Ridgeway, DNP, APN, NP-C, AOCN

Watch Video


Learn More On This Topic: Risk-Adapted Treatment of Acute Myelogenous Leukemia

Jean A. Ridgeway, DNP, APN, NP-C, AOCN, on treating acute myeloid leukemia.

What are the best ways to manage the side effects of AML therapies?

Jean A. Ridgeway, DNP, APN, NP-C, AOCN

Watch Video


Learn More On This Topic: Risk-Adapted Treatment of Acute Myelogenous Leukemia

Jean A. Ridgeway, DNP, APN, NP-C, AOCN, on treating acute myeloid leukemia.

What are the germline mutations in patients predisposed to MPN/MDS?

Sandra E. Kurtin, PhDc, ANP-C, AOCN

Watch Video


Learn More On This Topic: Risk-Adapted Treatment of Ph- Myeloproliferative Neoplasms

Sandra E. Kurtin, PhDc, ANP-C, AOCN, on treating Ph- myeloproliferative neoplasms.

What should I know about the JAK-STAT biochemical signaling pathway?

Sandra E. Kurtin, PhDc, ANP-C, AOCN

Watch Video


Learn More On This Topic: Risk-Adapted Treatment of Ph- Myeloproliferative Neoplasms

Sandra E. Kurtin, PhDc, ANP-C, AOCN, on treating Ph- myeloproliferative neoplasms.

What are the latest WHO disease definitions for diagnosing myeloproliferative neoplasms?

Sandra E. Kurtin, PhDc, ANP-C, AOCN

Watch Video


Learn More On This Topic: Risk-Adapted Treatment of Ph- Myeloproliferative Neoplasms

Sandra E. Kurtin, PhDc, ANP-C, AOCN, on treating Ph- myeloproliferative neoplasms.

What are the mechanisms of action and use of PD-1 inhibitors in the treatment of classical Hodgkin lymphoma?

Patrick J. Kiel, PharmD, BCPS, BCOP

Watch Video


Learn More On This Topic: Emerging Therapies for Hodgkin Lymphoma

Patrick J. Kiel, PharmD, BCPS, BCOP, on treating Hodgkin lymphoma.

What are the emerging therapies for relapsed or refractory classical Hodgkin lymphoma?

Patrick J. Kiel, PharmD, BCPS, BCOP

Watch Video


Learn More On This Topic: Emerging Therapies for Hodgkin Lymphoma

Patrick J. Kiel, PharmD, BCPS, BCOP, on treating hodgkin lymphoma.

What are the best care strategies for patients with relapsed/refractory multiple myeloma who need maintenance therapy?

Patrick J. Kiel, PharmD, BCPS, BCOP

Watch Video


Learn More On This Topic: Emerging Therapies for Multiple Myeloma

Patrick J. Kiel, PharmD, BCPS, BCOP: on treating multiple myeloma.

What are the prognostic factors and risk-adaptive strategies for making treatment decisions in follicular lymphoma?

Amy Goodrich, MSN, CRNP

Watch Video


Learn More On This Topic: Risk-Adapted Treatment of Indolent B-Cell Lymphomas: Application of Novel Agents

Amy Goodrich, MSN, CRNP, on treating follicular lymphoma.

What are the latest data on newly approved agents for primary, relapsed, and refractory follicular lymphoma?

Amy Goodrich, MSN, CRNP

Watch Video


Learn More On This Topic: Risk-Adapted Treatment of Indolent B-Cell Lymphomas: Application of Novel Agents

Amy Goodrich, MSN, CRNP, on treating follicular lymphoma.

What are the best strategies for managing the side effects of medications for follicular lymphoma?

Amy Goodrich, MSN, CRNP

Watch Video


Learn More On This Topic: Risk-Adapted Treatment of Indolent B-Cell Lymphomas: Application of Novel Agents

Amy Goodrich, MSN, CRNP, on treating follicular lymphoma.

How do I incorporate emerging therapies into treatment plans for patients with CLL?

Amy Goodrich, MSN, CRNP

Watch Video


Learn More On This Topic: Risk-Adapted Treatment of Indolent B-Cell Lymphomas: Application of Novel Agents

Amy Goodrich, MSN, CRNP, on treating chronic lymphocytic leukemia.

How useful is biomarker testing in choosing patients for immunotherapy?

Whitney Lewis, PharmD, BCOP

Watch Video


Learn More On This Topic: Immunotherapy: Treatment-Related Issues

Whitney Lewis, PharmD, BCOP, on biomarker testing.

What is the rationale for sequencing and combining immunotherapy with chemotherapy?

Whitney Lewis, PharmD, BCOP

Watch Video


Learn More On This Topic: Immunotherapy: Treatment-Related Issues

Whitney Lewis, PharmD, BCOP, on using immunotherapy vs chemotherapy.

What combination therapies lead to more durable responses?

Brianna Hoffner, MSN, ANP-BC, AOCNP, and Laura J. Zitella, MS, RN, ACNP-BC, AOCN

Watch Video


Learn More On This Topic: Immunotherapy: Treatment-Related Issues

Brianna Hoffner, MSN, ANP-BC, AOCNP, and Laura J. Zitella, MS, RN, ACNP-BC, AOCN, on current data on effective immunotherapies.

What are the differences between early and late adverse effects of immunotherapy treatments?

Brianna Hoffner, MSN, ANP-BC, AOCNP, and Laura J. Zitella, MS, RN, ACNP-BC, AOCN

Watch Video


Learn More On This Topic: Immune-Related Adverse Events

Brianna Hoffner, MSN, ANP-BC, AOCNP, and Laura J. Zitella, MS, RN, ACNP-BC, AOCN, on adverse effects of immunotherapy.

How do we understand response patterns in immunotherapy?

Brianna Hoffner, MSN, ANP-BC, AOCNP

Watch Video


Learn More On This Topic: Immunotherapy: Treatment-Related Issues

Brianna Hoffner, MSN, ANP-BC, AOCNP, on assessing response in immunotherapy.

How do the side effects of immunotherapy and chemotherapy agents differ?

Brianna Hoffner, MSN, ANP-BC, AOCNP

Watch Video


Learn More On This Topic: Immune-Related Adverse Events

Brianna Hoffner, MSN, ANP-BC, AOCNP, on immunotherapy and chemotherapy side effects.

Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.